Acta Diabetol 2021 Jul 2;58(7):869-880. Epub 2021 Mar 2.
Department of Endocrinology, Taihe Hospital, Hubei University of Medical, Shiyan, 442000, China.
Aims: The aim was to systematically review the efficacy and safety of sodium-glucose cotransporter inhibitor (SGLT2i) as an adjunct to insulin at different follow-up durations in randomized, double-blind clinical trials in patients with type 1 diabetes.
Methods: We conducted a search on Medline, Embase, and the Cochrane Library for relevant studies published before May 2020. According to the duration of follow-up, the subgroup analysis included four periods: 1-4, 12-18, 24-26, and 52 weeks. Read More